A look at one company’s experience with pharmacogenetic testing

… Pharmacogenetic testing is a hot topic, according to Dr. Tyler Amell, a partner at Morneau Shepell Ltd. The interest is mainly coming from mid- to large-sized companies, he says. “And sometimes, I’m actually getting questions on individual patients and individual employees, rather than an actual setting up programming to support employees.” The testing is a worthwhile consideration for plan sponsors, both in terms of time and money, according to Amell. “There’s ample evidence to show that personalized medicine is very much at the forefront with our approaches to treating people [in] this day and age, particularly for mental-health conditions. But it’s not limited to that, obviously. There’s definite return on investment from using this. . . . By using this approach, you’re essentially leapfrogging to the drug that is most likely going to produce the desired clinical effect in the patient or the worker.”

Read more on Benefits Canada.